Moe Alsumidaie

Companies that have piloted decentralized workflows are benefiting from technologies that support study operations in the disruption caused by COVID-19, but how will the rest survive the new norm?

Expert in rare disease patient registries discusses ways to address hurdles in setting up observational cohort clinical studies.

INmune Bio's Chief Executive Officer, Dr. R.J. Tesi, discusses the company's unique approach of decreasing neuroinflammation, as a new strategy to slow Alzheimer's disease.

ICH E6-R2 has taken another leap forward as quality-focused personnel have shifted focus to vendor oversight plans, essential document management, and evaluating quality tolerance limits in more depth.

Jing Zhao, Chief Business Officer of Refuge Biotechnologies, discusses how dead cas9 can be leveraged to completely control gene expression without making permanent edits as seen with CRISPR technology.

Tzvia Bader, CEO of TrialJectory, discusses how the company’s AI-powered technology platform is democratizing cancer care and expanding access to advanced new treatments.

With the Coronavirus causing significant disruptions in the clinical trials industry, Sponsors should expect data quality issues due to missed visits and a reduction in enrollment rates.

Ravi Jandhyala, Consultant Pharmaceutical Physician at Medialis and an expert in rare disease patient registries, discusses how to overcome clinical trial registry challenges.

Allyson Gage, Chief Medical Officer at Cohen Veterans Bioscience talks about her perspectives on platform trial design.

David Arthur, CEO of Salarius, discusses efficacy, collaborating with nonprofit institutes to obtain funding, and garnering patient support to increase recruitment in clinical trials.

Therapies aimed at correcting genes that cause diseases are gaining ground in biopharma, some are even specializing in specific mechanisms of action by targeting and modifying RNA through temporary and ongoing treatment. CEO at ProQR Therapeutics, Daniel de Boer, discusses how they are advancing RNA therapies in retinal disorders.

David Arthur, CEO of Salarius, discusses how companies like Salarius are incorporating endpoints into early-stage clinical trials that could offer a glimpse into efficacy.

Doug Manion, CEO of Kleo, explains how platform technology essentially involves the engineering of antibodies and biologics using linear process chemistry to enhance drug effectiveness.

Dr. Riam Shammaa of INTELLiSTEM discusses his discoveries, how he plans to tackle clinical trial and therapy development challenges, and what the future development of cell-gene based cancer treatments look like.

Seth Lederman, CEO of Tonix Pharmaceuticals, discusses their diverse research and development pipeline-including potential therapies for fibromyalgia, cocaine intoxication, and PTSD.

BioXcel Therapeutics Executives, Vimal Mehta and Vince O’Neill, discuss how they are actively using artificial intelligence to discover advanced therapies in CNS and oncology.

CEO of Synteract, Steve Powell, discusses the advantages that mid-sized CROs-like his own-offer emerging drug developers to navigate continually changing processes.

COO and CMO of BrainStorm, Ralph Kern, discusses how his company is overcoming challenges and advancing science in neurodegenerative disease.

Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.

Dr. Daniel Alkon, President & Chief Science Officer at Neurotrope, discusses novel approaches to AD therapy development and why his company chose to target patients with advanced AD for their own.

CEO of eXIthera, Neil Hayward, talks about his experience overcoming the challenges of starting up an emerging biopharmaceutical company, including the challenges of preclinical and early-stage development.

Benjamin Hughes, SVP of AI and Real-World Data at IQVIA, discusses how AI is changing the clinical trial paradigm, and how the technologies IQVIA is developing are different from other tech companies that specialize in AI/ML

Krishnan Nandabalan, CEO of InveniAI, discusses how artificial intelligence is shifting the clinical trial paradigm in studies for areas like oncology and the central nervous system.

Barbara Lopez Kunz, Global Chief Executive at the Drug Information Association discusses how involvement of patients in healthcare is critical for success.

The unforeseen challenges with clinical trial execution in gene therapy and regenerative medicine studies, such as unchanging FDA regulations, discussed.

Dominique Demolle, CEO of Tools4Patient, discusses the effect artificial intelligence is having on the statistical impact of clinical trial placebo response.

Yaky Yanay, CEO of Pluristem, talks with Moe Alsumidaie about his experience and the strategies Pluristem implemented in regenerative medicine clinical trials.

Yaky Yanay, CEO of Pluristem, will discuss his experience and the strategies Pluristem implemented in regenerative medicine clinical trials.

Chris Smith, COO of IQVIA Biotech, discusses with Moe Alsumidaie how large CROs are responding to EBP targets.

Tony Fiorino, Chief Medical Officer of electroCore, discusses challenges he has faced with device studies, and will elaborate on his experiences about the differences between device and drug trials.